

(A)


c-MET WT
c-MET G1085R
c-MET G1087E
c-MET N375S



(B)

c-MET WT
c-MET G1085R
c-MET G1087E
c-MET N375S

Cisplatin (1 mg/kg)



(C)

c-MET WT
c-MET G1085R
c-MET G1087E
c-MET N375S

Crizotinib (25 mg/kg)



(D)

c-MET WT
c-MET G1085R
c-MET G1087E
c-MET N375S

SU11274 (6 mg/kg)



Supplementary Figure S5. SCID mice were subcutaneously inoculated with endometrial cancer RL95-2 cells carrying either wild type or mutant *MET* (N375S, G1085R, or G1087E). The mice were treated with observation alone **(A)**, cisplatin 1 mg/kg **(B)**, crizotinib 25 mg/kg **(C)**, or SU1127 6 mg/kg **(D)** 1 week after tumor inoculation. The tumor size at the day when mice were sacrificed was shown.